Continuous IOP monitoring

Article

Investigating tolerability of a diagnostic device in healthy and glaucomatous patients

"The role of IOP fluctuation as an independent predictive factor for glaucoma progression is still controversial,"6–10 she added. "Goldmann applanation tonometry (GAT) has been the most widely established indirect method for measuring IOP for many decades and is the gold standard."11–14

"We tested the first model for use in humans for the first time in healthy subjects and in glaucoma patients with the primary objective to investigate tolerability and side effects of the device during and after a 24-hour IOP monitoring period," explained Dr Lorenz. Taking both healthy subjects and glaucoma patients and excluding anyone who had worn contact lenses before, the team placed one sensor in each patient's test eye and performed examinations both before and after the 24 hour wearing period.

"To evaluate the level of discomfort of the device in the study eye at 24 hours, a visual analogue scale (VAS) was presented to the subject. VAS for each subject was scored between 0 and 100 mm, the number corresponding to the distance in millimetres of the subject's mark on the VAS line from the left end. Secondary endpoints included best corrected visual acuity (BCVA), pachymetry, epithelial defects, conjunctival erythema and corneal topography," she said. "Additionally, subjects were asked to fill in a diary which was collected at the end of the study."

A test was also performed initially to ensure that healthy and glaucoma patients could be analysed together, as the device had never been formally tested in healthy subjects before. Dr Lorenz explained that if the glaucoma patients had demonstrated severe discomfort in this trial there would have been some difficulty in proving that it was not significantly associated with ocular surface disease, therefore, healthy subjects were required to be used as controls. "However, contrary to our expectations, no significant differences between the two groups could be demonstrated and both groups were combined for analysis," she asserted.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.